JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Comparison of efficacy and tolerability of single agent and double agent chemotherapy regimens in first-line treatment of elderly patients with her-2 negative metastatic gastric cancer
Abstract
Aims: Chemotherapy remains a cornerstone in treating metastatic gastric cancer (GC), yet the management of elderly patients, who often face distinct challenges, lacks comprehensive guidelines. The aim of this study was to compare the efficacy and side effects of single-agent and double-agent chemotherapy regimens in first-line treatment of elderly patients with HER-2 negative metastatic GC.
Methods: We retrospectively evaluated HER-2 negative metastatic GC patients aged 80 years and older who were treated at Van Yüzüncü Yıl University Medical Faculty Dursun Odabaşı Medical Center Oncology Clinic between 2010 and 2023. Demographic characteristics, treatment regimens and responses, prognostic factors, grade 3-4 toxicity, progression-free survival (PFS), and overall survival (OS) were analyzed.
Results: The mean age of 56 patients was 82.6 ± 2.3 years and 24 (42.9%) of them were women. Single-agent chemotherapy was administered to 33 (58.9%) patients, while 23 (41.1%) received double-agent chemotherapy. The median OS was 5 months (95% CI, 2.9 to 7.1) in the single-agent group and 10 months (95% CI, 4.2 to 15.8) in the double-agent group (p = 0.237), although there was a numerical difference, it was not statistically significant. Median PFS was longer with double-agent chemotherapy, but not statistically significant (6 months vs. 4 months, p = 0.668). No statistically significant difference was found in the side effect rates of patients receiving single and double-agent chemotherapy.
Conclusion: In our study, despite the absence of statistical significance in the survival rates among patients receiving double chemotherapeutic agents, their survival was twice as long as that of individuals receiving a single agent. Furthermore, no significant differences in terms of side effects were observed. These findings suggest that, even in individuals aged 80 years and older, a preference for double-agent chemotherapy should be considered when feasible.

Keywords : Chemotherapy, gastric cancer, elderly, first-line treatment

Download Article


1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
2. Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advancedgastric cancer. Cochrane Database Syst Rev. 2017;8(8):CD004064.
3. Ajani JA, D’Amico TA, Bentrem DJ, et al. Gastric cancer, version2.2022, NCCN clinical practice guidelines in oncology. J Natl ComprCanc Netw. 2022;20(2):167-192.
4. Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinicalpractice guideline for diagnosis, treatment and follow-up. Ann Oncol.2022;33(10):1005-1020.
5. Maddams J, Utley M, Møller H. Projections of cancer prevalence inthe United Kingdom, 2010-2040. Br J Cancer. 2012;107(7):1195-1202.
6. Hurria A, Lichtman SM. Clinical pharmacology of cancer therapies inolder adults. Br J Cancer. 2008;98(3):517-522.
7. Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia,Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (theInternational Cancer Benchmarking Partnership): an analysis ofpopulation-based cancer registry data. Lancet. 2011;377(9760):127-138.
8. Sezigin Y, Urun Y. Chemotherapy efficacy and tolerability inmetastatic gastric cancer patients aged 75 years and older. EJMI.2023;7(4):487-493.
9. Liao PW, Cheng SB, Chou CW, et al. Chemotherapy for metastaticgastric cancer: does Age Matter? A single-center, retrospective, real-world study. Clin Med Insights Oncol. 2022;16:11795549221123617.
10. Glimelius B, Ekström K, Hoffman K, et al. Randomized comparisonbetween chemotherapy plus best supportive care with best supportivecare in advanced gastric cancer. Ann Oncol. 1997;8(2):163-168.
11. Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survivaladvantage for irinotecan versus best supportive care as second-linechemotherapy in gastric cancer--a randomised phase III study of theArbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer.2011;47(15):2306-2314.
12. Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreatedgastric cancer: a randomized phase III trial comparing chemotherapyplus best supportive care with best supportive care alone. J Clin Oncol.2012;30(13):1513-1518.
13. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE.Chemotherapy in advanced gastric cancer: a systematic review andmeta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903-2909.
14. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study ofdocetaxel and cisplatin plus fluorouracil compared with cisplatin andfluorouracil as first-line therapy for advanced gastric cancer: a reportof the V325 Study Group. J Clin Oncol. 2006;24(31):4991-4997.
15. Hall PS, Swinson D, Cairns DA, et al. Efficacy of reduced-intensitychemotherapy with oxaliplatin and capecitabine on quality of lifeand cancer control among older and frail patients with advancedgastroesophageal cancer: the GO2 phase 3 randomized clinical trial.JAMA Oncology. 2021;7(6):869-877.
16. Graziano F, Santini D, Testa E, et al. A phase II study of weeklycisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-linechemotherapy for elderly patients with advanced gastric cancer. Br JCancer. 2003;89(8):1428-1432.
17. Trumper M, Ross PJ, Cunningham D, et al. Efficacy and tolerabilityof chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer.2006;42(7):827-834.
18. Hwang IG, Ji JH, Kang JH, et al. A multi-center, open-label,randomized phase III trial of first-line chemotherapy with capecitabinemonotherapy versus capecitabine plus oxaliplatin in elderly patientswith advanced gastric cancer. J Geriatr Oncol. 2017;8(3):170-175.
19. Sun DS, Jeon EK, Won HS, et al. Outcomes in elderly patients treatedwith a single-agent or combination regimen as first-line chemotherapyfor recurrent or metastatic gastric cancer. Gastric Cancer. 2015;18(3):644-652.
Article available in :
Volume 2, Issue 1, 2024
Page : 15-19
https://doi.org/10.51271/JCHOR-0029
Article Information
Received : 08 Oca 2024
Accepted : 07 Şub 2024
Published : 12 Şub 2024
Corresponding Author :

Gürkan Güner: Department of Medical Oncology, Medical Point Hospital, University of Economy, İzmir, Turkey

[email protected]
Citation : Güner G, Ürün M. Comparison of efficacy and tolerability of single agent and double agent chemotherapy regimens in first-line treatment of elderly patients with HER-2 negative metastatic gastric cancer. J Curr Hematol Oncol Res. 2024;2(1):15-19.

Read: 754
Cited: 0
Download : 165
_Footer